ArticleWomen's health reports (New Rochelle, N.Y.)
Dose-Dependent Efficacy of a Combined Standardized Extract of Fenugreek and Shatavari on Menopausal Symptoms: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.
Article in Women's health reports (New Rochelle, N.Y.). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the efficacy of Fenavari, a novel formulation of standardized Methods: This multicenter, randomized, double-blind, placebo-controlled, three-arm, parallel-group study enrolled women aged 40-60 years with menopausal symptoms. A total of 150 participants were randomized (1:1:1) to receive Fenavari 300 mg, Fenavari 500 mg, or placebo once daily for 84 days. Menopausal symptoms were assessed using the Menopause Rating Scale (MRS), sleep using the Pittsburgh Sleep Quality Index, mood using the Profile of Mood States, and anxiety using the Beck Anxiety Inventory at baseline and Days 14, 28, 56, and 84. Hormonal parameters (serum estradiol, progesterone, and follicle-stimulating hormone [FSH]) were measured at baseline and on Days 56 and 84. Safety and laboratory assessments were conducted throughout the study. Results: A total of 138 participants completed the study. Both Fenavari 300 mg and 500 mg significantly reduced MRS total scores from Day 14 through Day 84 compared with placebo (Fenavari 300 mg: -8.26 ± 0.46, Conclusion: Fenavari significantly improved menopausal symptoms across somatic, psychological, and vasomotor domains from Day 14 onward, and improved sleep, anxiety, and mood along with favorable hormonal changes and good tolerability, supporting its potential as a safe nonhormonal option for menopause management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.